Plasma lipid transfer proteins: The role of PLTP and CETP in atherogenesis

Area of Science:

• Lipid metabolism and cardiovascular disease research.
• Biochemistry and molecular biology of lipoprotein regulation.

Background:

• Cardiovascular diseases remain a leading cause of mortality globally and in Poland.
• Elevated LDL cholesterol, low HDL cholesterol, and high non-HDL cholesterol are key risk factors.
• Plasma phospholipid-transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) are crucial in lipoprotein metabolism.

Purpose of the Study:

• To explore the role of CETP and PLTP in cardiovascular disease pathogenesis.
• To evaluate the potential of targeting CETP for cardiovascular disease prevention.
• To address controversies surrounding PLTP's role in reverse cholesterol transport and atherogenesis.

Main Methods:

• Review of current scientific literature on CETP and PLTP.
• Analysis of studies investigating the impact of CETP inhibitors on cardiovascular health.
• Examination of research on PLTP activity and its association with various diseases.

Main Results:

• Reduced activity of CETP and PLTP is associated with lower LDL and higher HDL cholesterol levels.
• Clinical trials of some CETP inhibitors (e.g., torcetrapib, dalcetrapib) have yielded mixed or adverse results.
• The precise role of PLTP in reverse cholesterol transport and atherogenesis remains debated, with conflicting study findings.

Conclusions:

• Targeting CETP activity presents a potential strategy for reducing cardiovascular disease incidence, but requires careful consideration of drug efficacy and safety.
• Further investigation into PLTP's multifaceted role in lipoprotein metabolism and cardiovascular pathology is essential.
• Clarifying the impact of PLTP on atherogenesis is crucial for understanding its contribution to cardiovascular disease development.